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emergence and transmission of Neisseria gonorrhoeae
multidrug-resistant clones, especially those displaying
reduced susceptibility to cephaloporins, e.g., cefixime and
ceftriaxone.1e3 In addition, increasing reports on treatment
failures of oral cefixime, and later of injectable ceftriax-
one, currently the recommended first-line antibiotic for
gonorrhea treatment in many countries, have raised serious
concerns worldwide.1,4 Genetic mechanisms mediating
reduced cephaloporin susceptibility of N. gonorrhoeae is
complicated, including mutations in several chromosomal
genes such as penA, the gene that encodes the penicillin-
binding protein 2 (PBP2); porB1, an outer membrane
protein channel related to antibiotic entry; ponA, the
penicillin-binding protein 1 (PBP1); pilQ, the outer
membrane secretin PilQ; and mtrR, a repressor of the MtrC-
MtrD-MtrE efflux pump.
Among them, the polymorphisms in the penA allele are
the major contributors of resistance to cephaloporins in
N. gonorrhoeae.2,4e6 PBP2 is a membrane-bound enzyme
involved in cell wall biosynthesis and it is one of the
targets of the b-lactam antibiotics. The mutation in* Corresponding author. Research and Diagnostic Center, Centers
for Disease Control, Number 161, Kun-Yang Street, Taipei, Taiwan.
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http://dx.doi.org/10.1016/j.jfma.2012.03.015different positions of PBP2 may result in various levels of
minimal inhibition concentration (MIC) increase. PBP2s
with mosaic structure confer significantly higher MIC to
cephalosporins than those having non-mosaic
structures.1,2,4e6
Several reports on the emergence of cephalosporin-
resistant gonorrhea have indicated that the resistant
strains are mostly clonal and contain specific PBP2 types,
such as mosaic types X, XXXIV, and others.7 Thus, in view of
the important role of PBP2 types in cephalosporin resis-
tance, it is essential that the PBP2 types be characterized
precisely and named correctly.
We reviewed and summarized the names of PBP2s used
in different gonococcal studies during 2005e2011, and
found several discrepancies in the naming of PBP2. Since
2005, at least 37 sequence types of PBP2 have been
reported.1,2,4e6,8e12 For PBP2 sequence types I to XXIII
(except types X and XII), no conflict in assignment of PBP2
names was found among previous studies. However, for the
rest of the PBP2s, disagreements in nomenclature were
found: (1) seven PBP2 sequence types have discordant
names in different reports; and (2) under the PBP2 type
XXIV, there are two alternatives, one is mosaic and the
other is nonmosaic (see Table 1). In view of the increasing
international transmission of gonococcal strains with
reduced susceptibility to cephalosporins, unification in
PBP2 nomenclature is needed.& Formosan Medical Association. All rights reserved.
Table 1 The names of different PBP2 sequence types used in previous studies.
PBP2 name based
on ref. 4
Reference PBP2 name based
on refs. 1, 2, 5, and 6
Reference Other namea Reference
X*b 4 XXXV* 5
XII XXXVI 5
XXIV XXIV 6
XXV* XXV* 2 mosaic-3 10
XXVI* XXVI* 2 mosaic-4 10
XXVII* XXIV* 2 mosaic-2 10
XXVIII* XXVII* 2 PBP2 of strain 30/02 8
XXIX* XXVIII* 1, 2 PBP2 of strain 35/02c 8
XXXIII XXIX 2 PBP2 of strain 188/03 8
XXXV* XXXVIII* 5
XXXVI
a The name of a PBP2 sequence type in its source study.
b *indicates mosaic PBP2 types.
c The PBP2 of strain 35/02 in refs. 1, 2, and 8 was assigned as type XXVIII, but the amino acid sequence of penA allele in N. gon-
oeehoeae strain 35/02 (GenBank accession number ZP_06129591) in NCBI was identical to PBP2 type X. We are not sure whether these
two alleles are different.
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